rs1057519793
|
|
|
0.710 |
GeneticVariation |
BEFREE |
Previous report has demonstrated the type-II inhibitor ponatinib is the most potentially effective agent for RMS but still hard to starboard the V550E/L mutants.
|
31128178 |
2019 |
rs1057519793
|
|
A |
0.710 |
GeneticVariation |
CLINVAR |
Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
|
24124571 |
2013 |
rs1057519793
|
|
A |
0.710 |
GeneticVariation |
CLINVAR |
Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.
|
19809159 |
2009 |
rs1057519792
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
|
24124571 |
2013 |
rs1057519792
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
|
24124571 |
2013 |
rs1057519696
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.
|
22184391 |
2012 |
rs80357989
|
|
TGTAATGA |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs121913529
|
|
|
0.040 |
GeneticVariation |
BEFREE |
First, to compare YAP1 S127A and KRAS G12V-driven rhabdomyosarcomas, we re-analysed gene expression microarray datasets from mouse rhabdomyosarcomas caused by these genes.
|
30353028 |
2018 |
rs121913529
|
|
|
0.040 |
GeneticVariation |
BEFREE |
By contrast, mylz2:KRAS(G12D) tumors more closely resembled mature skeletal muscle and were most similar to well-differentiated human rhabdomyosarcoma in terms of gene expression. mylz2:KRAS(G12D) fish showed significantly improved survival compared with cdh15:KRAS(G12D) and rag2:KRAS(G12D) fish.
|
23821038 |
2013 |
rs121913529
|
|
|
0.040 |
GeneticVariation |
BEFREE |
We performed an overexpression screen of chromatin-modifying factors in a KRAS(G12D)-driven zebrafish model for RMS.
|
23705022 |
2013 |
rs121913529
|
|
|
0.040 |
GeneticVariation |
BEFREE |
An oncogenic G12D KRAS mutation was detected in both the epidermal component of the EN and in the rhabdomyosarcoma but not in the dermal component of the EN lesion or in unaffected tissues, including normal skin or blood.
|
20805368 |
2010 |
rs1444669684
|
|
|
0.020 |
GeneticVariation |
BEFREE |
First, to compare YAP1 S127A and KRAS G12V-driven rhabdomyosarcomas, we re-analysed gene expression microarray datasets from mouse rhabdomyosarcomas caused by these genes.
|
30353028 |
2018 |
rs1444669684
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Expression of Kirsten rat sarcoma viral oncogene [Kras(G12V)] and disruption of cyclin-dependent kinase inhibitor 2A (CDKN2A; p16p19) in prospectively isolated satellite cells gave rise to pleomorphic rhabdomyosarcomas (MyoD-, Myogenin- and Desmin-positive), whereas introduction of the same oncogenetic hits in nonmyogenic progenitors induced pleomorphic sarcomas lacking myogenic features.
|
22135462 |
2011 |
rs28934576
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Patient 1 with LFS and TP53(R273H) developed a rhabdomyosarcoma twice at the ages of 18 months and 21 years.
|
21484931 |
2011 |
rs28934576
|
|
|
0.020 |
GeneticVariation |
BEFREE |
One was a rhabdomyosarcoma with a missense mutation at codon 273, substituting histidine (His) for arginine (Arg).
|
9269965 |
1997 |
rs766121173
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The V550E/L and N535D/K mutations of FGFR4 in RMS can lead to strong drug resistance to almost all of the type-I inhibitors.
|
31128178 |
2019 |
rs104894228
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Furthermore, the HRAS c.37G>C mutation has never been related to any type of rhabdomyosarcoma.
|
29430633 |
2018 |
rs1131691021
|
|
|
0.010 |
GeneticVariation |
BEFREE |
First, to compare YAP1 S127A and KRAS G12V-driven rhabdomyosarcomas, we re-analysed gene expression microarray datasets from mouse rhabdomyosarcomas caused by these genes.
|
30353028 |
2018 |
rs762846821
|
|
|
0.010 |
GeneticVariation |
BEFREE |
First, to compare YAP1 S127A and KRAS G12V-driven rhabdomyosarcomas, we re-analysed gene expression microarray datasets from mouse rhabdomyosarcomas caused by these genes.
|
30353028 |
2018 |
rs2279343
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our results demonstrated that CYP2B6 rs2279343 may predict EFS in RMS patients and warrants future studies to clarify the pharmacogenetics of CPA in pediatrics.
|
27388155 |
2016 |
rs3211371
|
|
|
0.010 |
GeneticVariation |
BEFREE |
There was no association between rs3745274, rs3211371 genotypes and survival outcomes of RMS.
|
27388155 |
2016 |
rs147055703
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We performed an overexpression screen of chromatin-modifying factors in a KRAS(G12D)-driven zebrafish model for RMS.
|
23705022 |
2013 |
rs1196220479
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patient 1 with LFS and TP53(R273H) developed a rhabdomyosarcoma twice at the ages of 18 months and 21 years.
|
21484931 |
2011 |
rs104894229
|
|
|
0.010 |
GeneticVariation |
BEFREE |
To gain an understanding of the relationship between constitutional HRAS mutations and malignancy, HRAS was sequenced in an advanced biphasic rhabdomyosarcoma/fibrosarcoma from an individual with a 34G --> A mutation.
|
16372351 |
2006 |
rs121918453
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In a screen for mutations of PTPN11 in 7 cell lines and 30 fresh tumors of RMS and in 25 cell lines and 40 fresh tumors of NB, we identified a missense mutation (A72T) in an embryonal RMS patient.
|
16518851 |
2006 |